112 related articles for article (PubMed ID: 38745193)
1. Magnetically modified-mitoxantrone mesoporous organosilica drugs: an emergent multimodal nanochemotherapy for breast cancer.
Romaní-Cubells E; Martínez-Erro S; Morales V; Chocarro-Calvo A; García-Martínez JM; Sanz R; García-Jiménez C; García-Muñoz RA
J Nanobiotechnology; 2024 May; 22(1):249. PubMed ID: 38745193
[TBL] [Abstract][Full Text] [Related]
2. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
[TBL] [Abstract][Full Text] [Related]
3. Smart Cancer Cell Targeting Imaging and Drug Delivery System by Systematically Engineering Periodic Mesoporous Organosilica Nanoparticles.
Lu N; Tian Y; Tian W; Huang P; Liu Y; Tang Y; Wang C; Wang S; Su Y; Zhang Y; Pan J; Teng Z; Lu G
ACS Appl Mater Interfaces; 2016 Feb; 8(5):2985-93. PubMed ID: 26767305
[TBL] [Abstract][Full Text] [Related]
4. Nanostructured lipid-carrageenan hybrid carriers (NLCCs) for controlled delivery of mitoxantrone hydrochloride to enhance anticancer activity bypassing the BCRP-mediated efflux.
Ling G; Zhang T; Zhang P; Sun J; He Z
Drug Dev Ind Pharm; 2016 Aug; 42(8):1351-9. PubMed ID: 26754913
[TBL] [Abstract][Full Text] [Related]
5. Overview of stimuli-responsive mesoporous organosilica nanocarriers for drug delivery.
Guimarães RS; Rodrigues CF; Moreira AF; Correia IJ
Pharmacol Res; 2020 May; 155():104742. PubMed ID: 32151682
[TBL] [Abstract][Full Text] [Related]
6. Mesoporous silica nanoparticles with organo-bridged silsesquioxane framework as innovative platforms for bioimaging and therapeutic agent delivery.
Du X; Li X; Xiong L; Zhang X; Kleitz F; Qiao SZ
Biomaterials; 2016 Jun; 91():90-127. PubMed ID: 27017579
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone- and Folate-TPGS2k Conjugate Hybrid Micellar Aggregates To Circumvent Toxicity and Enhance Efficiency for Breast Cancer Therapy.
Guissi NE; Li H; Xu Y; Semcheddine F; Chen M; Su Z; Ping Q
Mol Pharm; 2017 Apr; 14(4):1082-1094. PubMed ID: 28191959
[TBL] [Abstract][Full Text] [Related]
8. Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.
Zhuang J; Chen S; Hu Y; Yang F; Huo Q; Xie N
Int J Nanomedicine; 2021; 16():1961-1976. PubMed ID: 33727809
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy.
Ali OM; Bekhit AA; Khattab SN; Helmy MW; Abdel-Ghany YS; Teleb M; Elzoghby AO
Colloids Surf B Biointerfaces; 2020 Apr; 188():110824. PubMed ID: 32023511
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Homing Cell-Penetrating Peptide Linked to Colloidal Mesoporous Silica Encapsulated (-)-Epigallocatechin-3-gallate as Drug Delivery System for Breast Cancer Therapy in Vivo.
Ding J; Yao J; Xue J; Li R; Bao B; Jiang L; Zhu JJ; He Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18145-55. PubMed ID: 26225796
[TBL] [Abstract][Full Text] [Related]
11. Ultrasmall mesoporous organosilica nanoparticles: Morphology modulations and redox-responsive biodegradability for tumor-specific drug delivery.
Yu L; Chen Y; Lin H; Du W; Chen H; Shi J
Biomaterials; 2018 Apr; 161():292-305. PubMed ID: 29427925
[TBL] [Abstract][Full Text] [Related]
12. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
[TBL] [Abstract][Full Text] [Related]
13. Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells.
Croissant JG; Fatieiev Y; Omar H; Anjum DH; Gurinov A; Lu J; Tamanoi F; Zink JI; Khashab NM
Chemistry; 2016 Jul; 22(28):9607-15. PubMed ID: 27245497
[TBL] [Abstract][Full Text] [Related]
14. A Facile Multi-interface Transformation Approach to Monodisperse Multiple-Shelled Periodic Mesoporous Organosilica Hollow Spheres.
Teng Z; Su X; Zheng Y; Zhang J; Liu Y; Wang S; Wu J; Chen G; Wang J; Zhao D; Lu G
J Am Chem Soc; 2015 Jun; 137(24):7935-44. PubMed ID: 26030506
[TBL] [Abstract][Full Text] [Related]
15. A pH/ROS-responsive, tumor-targeted drug delivery system based on carboxymethyl chitin gated hollow mesoporous silica nanoparticles for anti-tumor chemotherapy.
Ding X; Yu W; Wan Y; Yang M; Hua C; Peng N; Liu Y
Carbohydr Polym; 2020 Oct; 245():116493. PubMed ID: 32718608
[TBL] [Abstract][Full Text] [Related]
16. Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells.
Zhang BB; Chen XJ; Fan XD; Zhu JJ; Wei YH; Zheng HS; Zheng HY; Wang BH; Piao JG; Li FZ
Acta Pharmacol Sin; 2021 May; 42(5):832-842. PubMed ID: 33824461
[TBL] [Abstract][Full Text] [Related]
17. Fabrication of multifunctional triple-responsive platform based on CuS-capped periodic mesoporous organosilica nanoparticles for chemo-photothermal therapy.
Cheng X; Li D; Lin A; Xu J; Wu L; Gu H; Huang Z; Liu J; Zhang Y; Yin X
Int J Nanomedicine; 2018; 13():3661-3677. PubMed ID: 29983561
[TBL] [Abstract][Full Text] [Related]
18. Redox-triggered mitoxantrone prodrug micelles for overcoming multidrug-resistant breast cancer.
Qiao H; Zhu Z; Fang D; Sun Y; Kang C; Di L; Zhang L; Gao Y
J Drug Target; 2018 Jan; 26(1):75-85. PubMed ID: 28583001
[TBL] [Abstract][Full Text] [Related]
19. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
20. Gossypol-Capped Mitoxantrone-Loaded Mesoporous SiO2 NPs for the Cooperative Controlled Release of Two Anti-Cancer Drugs.
Heleg-Shabtai V; Aizen R; Sharon E; Sohn YS; Trifonov A; Enkin N; Freage L; Nechushtai R; Willner I
ACS Appl Mater Interfaces; 2016 Jun; 8(23):14414-22. PubMed ID: 27186957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
